Abbott Showcases Fourth-Generation MitraClip™ in China: Personalized, Minimally Invasive Therapy for Mitral Regurgitation

2022Year11Month6Day, at the 5th China International Import Expo, Abbott, a global leading healthcare company, unveiled its fourth generationMitraClip^TMThe China debut of the transcatheter mitral valve clip and steerable guiding catheter, with iterative upgrades in life science technology, offers more personalized and precise treatment options for patients with moderate to severe mitral regurgitation who are at high surgical risk. On the same day, Abbott also celebrated at the CIIE venue.MitraClip^TMSuccessfully Completed in China500Minimally Invasive Interventional Surgery for Mitral Regurgitation.

MitraClip^TMSuccessfully Completed in China500Celebration of Minimally Invasive Mitral Valve Regurgitation Surgery

Mitral regurgitation is one of the most common heart valve diseases, referring to the insufficient closure of the mitral valve in a patient's heart, causing blood to flow back from the left ventricle into the left atrium. Moderate to severe mitral regurgitation seriously affects the physical function and quality of life of patients. If not treated actively, it increases the risk of arrhythmia, stroke, and even death for the patient. It is estimated that the number of patients with moderate to severe mitral regurgitation in China is1,000More than 10,000, of which75The prevalence rate among people aged above is as high as10%. Due to the relatively high risk of traditional open-chest surgery for elderly patients, the percentage of elderly patients receiving surgical treatment is lower.2%。

MitraClip^TMThrough transcatheter minimally invasive technology, patients with moderate to severe mitral regurgitation are provided with a minimally invasive surgical option that does not require thoracotomy, extracorporeal circulation support, has a short operation time, and high safety. This is the fourth generation making its debut in China.MitraClip^TMOffers both simultaneous and independent leaflet grasping options to optimize the clamping effect during surgery; enables controlled steering of the mitral valve clip during the procedure, which helps monitor left atrial pressure and provides4Different models of mitral valve clips to better accommodate the unique mitral valve anatomy of patients, offering more personalized options.

The Fourth GenerationMitraClip^TMTranscatheter Mitral Valve Clip and Steerable Guide Catheter

Liu Weiting, General Manager of Abbott Structural Heart Disease in Greater China, said:“MitraClip^TMAfter its debut at the third CIIE, it received widespread attention from all sectors, and its clinical application has been proceeding smoothly. This year, we are bringing our next-generation product to the CIIE for its China premiere, hoping that the CIIE will be...‘Golden Key’With the boost, Abbott can accelerate the rollout of more cutting-edge life technologies.‘Four-Leaf Clover’, transforming from exhibits into practical products that deliver tangible benefits, benefiting more patients in China.”

Globally,MitraClip^TMHas accumulated19Years of research and clinical use experience, with over cases used15Tens of thousands of cases, highly recognized in the industry, including being listed by the globally renowned Cleveland Clinic.2020Top Ten Medical Innovations of the Year and the Galien Foundation's2020Best Medical Technology Award, etc.

Talking aboutMitraClip^TMIn clinical applications in China, Academician Ge Junbo highly praised:“MitraClip^TMThrough transcatheter minimally invasive technology, it has brought a new option for high-risk surgical patients with moderate to severe mitral regurgitation, also helping to open up a new landscape for minimally invasive interventional treatment of mitral regurgitation in China. It is gratifying to see that this innovative device has successfully contributed to procedures in China.500More than one surgery, with the expectation that it will have broader applications in the future, helping to optimize the treatment of heart valve diseases and benefit more patients.”

From2020Year6Since its approval for marketing in China in the month and its first public display at the third CIIE, thanks to the spillover effects of the CIIE,MitraClip^TMIn a short period of time from100The application of this surgical technique has rapidly developed, and to date, the cumulative number of clinical cases in China has broken through.500For example, while validating its clinical safety and effectiveness, it also marks China's transcatheter mitral regurgitation intervention entering a brand-new minimally invasive era.

Professor Zhou Daxin from the Department of Cardiology, Zhongshan Hospital, Fudan University, stated:“MitraClip^TMIt has been used for many years abroad and has rich clinical data. Currently, in ChinaMitraClip^TMThe early results of the surgery are consistent with foreign reports, showing good outcomes. From the clinical results,MitraClip^TM The listing not only saved the lives of a group of patients but also fully empowered personalized minimally invasive treatment for mitral regurgitation.”